Samed Group

What Samed Group does

Gruppo Samed (legal entity Tecno Samed Società Consortile A R.l.) is a privately held Italian hospital network headquartered in the Catania metropolitan area of Sicily, founded in 2003 and operating through six integrated facilities: Casa di Cura Musumeci Gecas (multi-specialty surgical hospital in Gravina di Catania), Istituto Oncologico del Mediterraneo (IOM) and IOM Ricerca (high-specialty oncology center with in-house molecular diagnostics and biotechnology), REM Catania and REM Viagrande (diagnostic imaging and radiotherapy/nuclear medicine), and Villa Lisa (residential care/RSA and outpatient physiotherapy). The group is accredited with the Italian National Health Service (SSN) and serves both public-payor patients and private/insured patients, marketing the dual-channel proposition "NO liste, NO ticket, NO iter del SSN" to insured users. Core service lines include robotic-assisted orthopedic surgery (knee and hip prostheses, ~600 implants per year, 108 robotic knee surgeries in 2022 ranking 2nd in Italy), G-scan Brio upright MRI diagnostics, Endopredict genomic testing for breast cancer (sole accredited center in Sicily), FREMS electrostimulation for neuropathic pain, advanced rehabilitation with VR-augmented motion analysis, and molecular diagnostics/biotechnology research.

The group operates with 513 collaborators delivering 526,896 inpatient stays and 1,242,684 outpatient services annually. Revenue is generated through SSN tariff reimbursement for accredited services, direct private patient payments, and insurance company billing. Distribution is direct via facility-based care, an online CUP (Centro Unico di Prenotazione) booking system, and referrals from Breast Units across Sicily; the group also markets through health-information content (Pillole di Salute), press coverage, and community health events. Research activities are coordinated through IOM Ricerca and partnerships with the University of Catania, University of Messina, University of Turin, CNR Catania, INFN Catania, Istituto Superiore di Sanità, and EU/national consortia including HEAL ITALIA, BiLiGeCT, and DiOncoGen. Co-founder Avv. Ettore Denti passed away in February 2025, marking a leadership transition at the privately held consortium.

Name

Samed Group

Legal name

Tecno Samed Società Consortile A R.l.

Website

https://grupposamed.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Gruppo Samed is a private SSN-accredited hospital network in Catania, Sicily, operating oncology, robotic orthopedic surgery, radiotherapy, molecular diagnostics, and rehabilitation facilities under the Tecno Samed consortium, serving public-payor and private patients through six integrated sites.

Ownership category

akta.pro rank

Headquarters

HQ city

Viagrande

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Hospital and clinical services: Private hospital network providing medical services to patients through accredited facilities. Revenue generated from SSN (National Health Service) accredited services, private patients, and insurance companies. NO ticket, NO waiting lists for private patients.
2. Diagnostic services: Imaging diagnostics, laboratory tests, and specialized diagnostic services for both inpatients and outpatients.
3. Scientific research: Research projects funded by national and regional programs including HEAL ITALIA, BiLiGeCT, and DiOncoGen projects.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels4 records

Core offering

Gruppo Samed is a private hospital network operating four integrated facilities in the Catania metropolitan area of Sicily, providing multi-specialty medical, surgical, oncological, diagnostic imaging, radiotherapy, nuclear medicine, rehabilitation, and residential care services. The group combines clinical practice with scientific research, offering advanced services including robotic orthopedic surgery, genomic testing for breast cancer, and molecular diagnostics, while serving both SSN-accredited public patients and private/insured patients.

Product overview

Gruppo Samed is a private hospital network integrating four main facilities: Casa di Cura Musumeci Gecas (multi-specialty surgical hospital), Istituto Oncologico del Mediterraneo (oncology center with IOM Ricerca for molecular diagnostics), REM Radioterapia (radiotherapy/nuclear medicine), and Villa Lisa (residential care/rehabilitation). The group combines scientific research with clinical practice to deliver personalized patient care. Key technology-enabled services include robotic orthopedic surgery (over 600 joint replacements annually), G-scan Brio MRI for upright imaging, Endopredict genomic testing for breast cancer, and advanced rehabilitation. With 513 collaborators serving 526,896 inpatients and 1,242,684 outpatient visits annually, it serves the metropolitan area of Catania, Sicily.

Differentiator

Problem solved

Functional benefit

Products and services

• Casa di Cura Musumeci Gecas Multi-specialty medical-surgical hospital in Gravina di Catania offering services including robotic orthopedic surgery, general surgery, urology, pneumology, nutrition, and rehabilitation. Accredited with the Italian National Health Service (SSN).
• Istituto Oncologico del Mediterraneo (IOM) High-specialty departmental oncology center combining clinical care with scientific research. Offers molecular diagnostics and biotechnology services through IOM Ricerca.
• REM Radioterapia Advanced radiotherapy and nuclear medicine services at the Viagrande location, part of the group's diagnostic imaging and treatment capabilities.
• Villa Lisa Residential Healthcare Facility (RSA) and physiotherapy outpatient clinic providing assisted living and rehabilitation services.
• Robotic Orthopedic Surgery Robotic navigation surgery for knee and hip replacement procedures using computer-assisted 3D planning and robotic arm precision for prosthetic placement. Over 600 knee and hip implants performed annually.
• G-scan Brio MRI Innovative open MRI system enabling diagnostic imaging in upright position for more precise evaluation of spine and joints (shoulder, elbow, wrist, hand, hip, knee, ankle, foot).
• Endopredict Genomic Test Genomic test for breast carcinoma that predicts chemotherapy benefit, allowing patients to avoid unnecessary treatment. IOM is the only accredited center in Sicily for this test.
• Rehabilitation and Physiotherapy Outpatient Clinic Rehabilitation outpatient clinic offering physiotherapy and physio-kinesitherapy with equipment including Walker View (motion analysis with virtual reality) and Fisio Frems (for inflammation and sports injuries).
• FREMS Electrostimulation FREMS (Functional Electronic Regeneration) is a painless electrostimulation therapy providing analgesic and anesthetic effects for neuropathic pain, diabetic neuropathy, and trophic ulcers.
• Pneumology Service Pneumology unit offering diagnosis and treatment of respiratory diseases including COPD, asthma, and sleep-related breathing disorders. Authorized by SSN for all COPD medications including fixed-dose combinations.
• Nutrition and Clinical Nutrition Service Nutrition clinic providing dietary counseling and personalized nutrition plans for obesity, metabolic syndrome, cardiovascular risk, diabetes, and general wellness.

Quantifiable outcome

• 108 robotic knee surgeries in 2022 (2nd in Italy)
• +7 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

Partnerships

16 partnerships are on record, tiered core, major and minor.

• Fondazione IOMcoreStrategic or Co-development PartnerFoundation supporting IOM research activities, including funding for patient accommodation expenses for radiotherapy patients
• Istituto di Scienze Neurologiche del CNR di CataniamajorStrategic or Co-development PartnerCollaboration with National Research Council institute for neurological sciences research
• Università degli Studi di CataniamajorStrategic or Co-development PartnerAcademic partnership with University of Catania for research collaboration
• Università degli Studi di MessinamajorStrategic or Co-development PartnerAcademic partnership with University of Messina for research collaboration
• Università di TorinomajorStrategic or Co-development PartnerAcademic partnership with University of Turin for research collaboration
• Istituto Nazionale di Fisica Nucleare - Sez. CataniamajorStrategic or Co-development PartnerCollaboration with National Institute for Nuclear Physics for advanced research
• Istituto Superiore di SanitàmajorStrategic or Co-development PartnerPartnership with Italian National Health Institute for public health research
• Vera Salus Ricerca S.r.l.minorStrategic or Co-development PartnerResearch collaboration partner for health research projects
• Alphagenics BiotechminorStrategic or Co-development PartnerBiotechnology partnership for advanced diagnostic and therapeutic solutions
• CINMPISminorStrategic or Co-development PartnerResearch consortium partnership for biomedical research
• Ca.Re.Bios S.r.l.minorStrategic or Co-development PartnerResearch partnership for biosciences and biotechnology development
• Cogentech S.c.a.r.l.minorStrategic or Co-development PartnerResearch consortium partnership for innovative technology development
• HEAL ITALIAmajorStrategic or Co-development PartnerEuropean project 'Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine' - active research collaboration involving multiple institutions
• BiLiGeCT ProjectmajorStrategic or Co-development PartnerProject 'Biopsie Liquide per la Gestione Clinica dei Tumori' (Liquid Biopsies for Clinical Management of Tumors) - funded by MIUR, involving multiple research institutions
• DiOncoGen ProjectmajorStrategic or Co-development PartnerProject 'Diagnostica Innovativa' (Innovative Diagnostics) - funded by Regione Siciliana, developing new diagnostic approaches for cancer
• Drug Delivery ProjectminorStrategic or Co-development PartnerProject 'Drug Delivery: veicoli per un'innovazione sostenibile' (Vehicles for Sustainable Innovation) - developing innovative drug delivery systems

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Gruppo San Donato: Italy's largest private hospital group with multi-specialty and oncology offerings; a broad incumbent that competes with Gruppo Samed in the Italian private healthcare market, particularly in oncology and specialty surgery.
• HCA Healthcare: Large US for-profit hospital operator serving diverse patient populations including SSN-equivalent insured/uninsured segments; analogous as a multi-facility for-profit private hospital network with outpatient diagnostics and oncology.
• Ramsay Santé: Leading European private hospital and clinic operator (France/Scandinavia), with a similar mix of multi-specialty hospitals, oncology, imaging, and rehabilitation; directly comparable as a European private multi-facility healthcare group.
• Humanitas: Major Italian private hospital network integrating research (IRCCS) with multi-specialty clinical care and university partnerships; directly comparable in combining research-clinical integration with a multi-facility private hospital model, though at much greater scale.
• Fresenius Helios: Largest European private hospital operator, providing multi-specialty and specialty hospital care across Germany and Spain; a broad incumbent comparable to Samed as a multi-specialty private hospital network with research partnerships.
• IRCCS Istituto Nazionale dei Tumori (INT Milan): Italy's premier public oncology research hospital combining clinical care with translational research; comparable in oncology clinical-research integration and precision medicine capabilities to IOM.

Direct peers

• Affidea: European network of diagnostic imaging and outpatient centers, including in Italy; comparable to REM Catania/Viagrande in diagnostic imaging services and outpatient ambulatory operations.
• Gruppo Maria Cecilia Hospital: Italian private multi-specialty hospital group offering accredited surgical, cardiac, and oncological services; comparable as a private multi-facility Italian hospital network serving SSN and insured patients.
• Istituto Europeo di Oncologia (IEO): High-specialty oncology institute in Milan integrating clinical care with molecular diagnostics and genomic research; closely comparable to Samed's IOM in mission, research-clinical integration, and precision oncology positioning, though operating at a national-international scale.

Regional players

• Villa Maria Cotignola (Maria Cecilia Hospital group): Italian private specialty hospitals (orthopedic focus); comparable as a private multi-specialty surgical provider in Italy with orthopedic and rehabilitation service lines similar to those at Casa di Cura Musumeci Gecas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/casadicuramusumeci
• LinkedInlinkedin.com/company/istituto-oncologico-del-mediterraneo-s.p.a.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Samed Group